Towards Healthcare
NGS-Based RNA-Sequencing Market Expands at 20.1% CAGR by 2034

NGS-Based RNA-Sequencing Market Forecast 2025 Explosive Growth Driven by AI, Precision Medicine

According to market projections, the global NGS-based RNA-sequencing market, valued at USD 3.74 billion in 2024, is anticipated to reach USD 23.52 billion by 2034, growing at a CAGR of 20.1% over the next decade. The market is expanding due to its high accuracy in analyzing gene expression and detecting rare transcripts. Growing use in disease research, especially cancer and infectious diseases, is further boosting its demand.

Content

  • Insight Code: 5886
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

The NGS-based RNA-sequencing market is projected to reach USD 23.52 billion by 2034, growing at a CAGR of 20.1% from 2024 to 2034.

North America is currently leading the healthcare cybersecurity market due to its well-established healthcare infrastructure, strong presence of leading sequencing technology providers, and significant investment in genomics research.

Some key players include Illumina, Inc., Thermo Fisher Scientific, Oxford Nanopore Technologies, Pacific Biosciences (PacBio), and Agilent Technologies QIAGEN, Takara Bio Inc.

Unlike microarrays, RNA-Seq does not rely on pre-designed probes and can detect novel transcripts, rare variants, and a wider dynamic range of gene expression.

India Brand Equity Foundation, Food and Drug Administration, U.S. Environmental Protection Agency, European Medicines Agency, and National Medical Products Administration.
Any Questions